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Abstract
Background: This scoping review investigates the relationship between governance, pharmacovigilance, and Agencia
Nacional de Vigilancia Sanitaria (ANVISA) in Brazil, which has authority over Brazil's national pharmaceutical policy, drug
registration and coordination of the national pharmacovigilance system. The purpose is to investigate opportunities for
effective pharmacovigilance.
Methods: Sixty-three terms pertaining to pharmacovigilance in Brazil and ANVISA, global institutions, pharmaceutical
industry, and civil society were searched in thirteen relevant databases on November 17-18, 2013. Using a
pharmacogovernance framework we analyzed ANVISA's pharmacogovernance: the manner in which governing
structures, policy instruments, and institutional authority are managed to promote societal interests for patient
safety due to medication use. The integration of transnational policy ideas for regulatory governance into
pharmacogovernance in Brazil was also investigated.
Results: Brazil's policy, laws, and regulations support ANVISA's authority to ensure access to safe medicines and health
products however ANVISA's broad mandate and gaps in pharmacogovernance account for regional disparities in
monitoring and assessing drug safety. Gaps in pharmacogovernance include: equity and inclusiveness; stakeholder
coordination; effectiveness and efficiency; responsiveness; and intelligence and information.
Conclusions: Pharmacogovernance that addresses 1) regional resource disparities, 2) federal and state lack of
coordination of pharmacovigilance regulations, 3) asymmetric representation in the pharmaceutical regulatory
agenda and which 4) disaggregates regulatory authority over health and commercial sectors would strengthen
pharmacovigilance in Brazil.
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Introduction
Pursuant to Article 196 of the Brazilian Constitution,
all Brazilians have the right to health [1–3]. The Con-
stitutional commitment to health for its population
includes access to safe, effective, quality essential medi-
cines; guidelines to promote rational use; and cost control
[3] as expressed in Brazil’s National Medicines Policy
(NMP). One key challenge the Federal government has
faced is how to determine what governance, regulations
and policy instruments best fulfill Brazilian’s constitutional
right to health; including assuring nationwide equity in
monitoring, assessing, and communicating drug safety
risk. Accordingly, we investigate pharmacogovernance in
Brazil and the Agência Nacional de Vigilância Sanitária
(ANVISA) regulatory governance for their impact on
pharmacovigilance (the science and activities relating to
detecting, assessing, understanding and preventing ad-
verse effects or other possible drug-related problems).
We define pharmacogovernance as the manner in
which governing structures; policy instruments and insti-
tutional authority (ability to act, implement and enforce
norms, policies and processes) are managed to promote
societal interests for patient safety and protection from
adverse drug events. Pharmacogovernance embraces a
culture that supports drug safety and contributes to
maintaining a healthy population, which the state and
corporate sector advances as aligned with pharmacovigi-
lance [4]. The absence of strong pharmacogovernance
undermines stewardship for postmarket drug safety,
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safety signal detection, risk communication and rational
medicine use. Weak pharmacogovernance therefore
entails a lack of oversight and accountability that
may negatively affect pharmacovigilance by:
 Creating opportunities for corruption to emerge [5–7];
 Creating institutional conflicts of interest, whereby
regulators are dually responsible for protecting
patient safety and industry competitiveness [8–10];
 De-incentivizing adoption of legislation and norms
for pharmacovigilance; and
 De-incentivizing detection of adverse drug reactions
(ADR) [5–7].
These negative outcomes of deficient pharmacogover-
nance are at odds with public health needs and the
constitutional right to health in Brazil.
We also investigated whether governance by the Agên-
cia Nacional de Vigilância Sanitária (ANVISA) and sup-
port from the international community are sufficient to
ensure postmarket drug safety across Brazil. Specifically,
we investigated how global actors’ policy ideas for regu-
latory governance (e.g., transparency and accountability)
were integrated into pharmacogovernance in Brazil.
Global actors were broadly defined as agents that in-
fluence public policy in multiple countries. They in-
cluded employees of the World Health Organization/
Pan American Health Organization (WHO/PAHO),
US Food and Drug Administration (FDA), Global Fund,
European Medicines Agency (EMA) and others that have
provided pharmacovigilance guidelines, best practices,
training, regulatory norms, technical expertise and access
to global knowledge networks [11–16].
We employ Ideation Theory to frame our understanding
of how and why global actors’ policy ideas and norms
pertaining to pharmacovigilance have gained traction in
Brazil. Ideation Theory suggests that a meaningful feature
of global actors is their capacity to convert ‘soft power’ into
‘hard power’ whereby global actors’ policy ideas and know-
ledge influence the policy agendas, policy tools, legislation,
and practices of recipient countries [17]. Soft power repre-
sents a persuasive approach that is taken to shape or co-
opt government policy preferences or public opinion. The
power to influence rests in perceived legitimacy or shared
values [18]. Norms are presented as a ‘toolbox’ from which
countries choose according to perceived relevance.
Ideation Theory suggests that policy uptake usually re-
quires collaboration between national and transnational
policy actors’ with technical and financial support [19].
New ideas (e.g., such as the use of policy tools for ana-
lyses of regulatory policy) are adopted to the extent that
they respond to concrete policy problems, resonate with
the interest and ideas of key actors and are brought to
the attention of relevant public agencies that have the
structural capacity to implement the new ideas [20]. The
policy ideas are reinforced through peer learning. Peer
learning is used as a strategy for the diffusion of global
development agencies’ policy ideas to poor and develop-
ing countries [17, 21].
Our paper is organized as follows. First, the evolution of
pharmacovigilance and regulatory authority over postmar-
ket drug safety in Brazil is described. Next, our search
methodology is described following the STARLITE report-
ing criteria. Following, our research findings are reported
for each of the literature typologies we identified. Lastly,
recommendations to advance pharmacogovernance and
pharmacovigilance in Brazil are provided.
Background
The 1990’s was marked by a groundswell of discourse sup-
porting pharmacovigilance by domestic and global actors.
Support for pharmacovigilance grew in Brazil’s univer-
sities, consumer advocacy groups, drug information cen-
ters, and health professional associations during the 1990s
[22]. State pharmacovigilance centers and drug informa-
tion centers (Centros de Informação de Medicamentos)
were established in São Paulo, Ceará, Paraná and Mato
Grosso do Sul during the period between 1989 and 1998
[16, 22–25]. Pharmacovigilance was also the focus of the
IV Brazilian Congress on the Surveillance of Drugs (1997),
Conference of Brazilian Society of Hospital Pharmacy I
and II, and the 1st Brazilian Seminar on Pharmacoepide-
miology [16]. Global actors’ policy ideas during this
period, as later described in this paper, served as a catalyst
for discussions regarding nationwide pharmacovigilance
systems. The disseminated policy ideas influenced state
pharmacovigilance initiatives in Brazil [14] (Fig. 1).
The Agência Nacional de Vigilância Sanitária (ANVISA)
was established in 1999. ANVISA ’s mandate is to protect
and promote population health and ensure access to safe
medicines, health products and services [3, 26]. It is one of
Brazil’s largest regulatory agencies; overseeing the imple-
mentation of aspects of Brazil’s NMP [27, 28]. ANVISA reg-
ulates products, sectors and services related to health and
numerous areas not directly relevant to pharmaceuticals or
medical devices (e.g., foods, tobacco, agricultural chemicals,
airports, and border surveillance) although much of its re-
sources are allocated to non-health sectors [26, 29]. It regu-
lates products and services that are valued at approximately
25 percent of Brazil’s gross domestic product [29].
ANVISA’s governance reflects the reform agenda
championed by President Fernando Henrique Cardoso
beginning in 1995 and continuing throughout his presi-
dency. Cardoso’s endorsement of regulatory oversight
led to a surge in the creation of newly structured regula-
tory authorities [30, 31]. ANVISA’s governance also
reflected global actors’ ideas for regulatory governance
that were circulated during the 1990s [29, 30].
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The post 2000 period
Brazil’s National Pharmacovigilance System (NPS) was
adopted in 2001. The NPS is managed by the Pharma-
covigilance Unit [27] and coordinated by ANVISA
[27, 28]. The National Center for Monitoring of Medi-
cines (CNMM) was also created in 2001 following the
meglumine tragedy (2000) that resulted in hundreds of
fatal ADRs [14, 27, 32]. The emergence of yet another
incident of serious and fatal ADRs resulting from the use
of medicines (e.g. thalidomide in1960) reinforced to the
Federal government the need for governing structures and
institutional authority over drug safety in Brazil. Today,
the CNMM is headquartered in the Pharmacovigilance
Unit and is responsible for planning, coordinating and
supervising the formulation and implementation of oper-
ational guidelines and technical norms for medicines
safety, rational use and surveillance.
Like many areas of the health system governance, re-
sponsibilities are shared at different levels. Both ANVISA
and Brazilian state governments have responsibility for
pharmacovigilance. State Centros de Vigilância Sanitária
(CVS) are responsible for implementing policy and
practices to reduce ADRs and poor quality medicines.
Pharmacosurveillance, monitoring drug adverse-effects
for signals of safety issues, is carried out by regional
pharmacovigilance centers in 193 sentinel hospitals and
sentinel pharmacies as part of the Notifying Pharmacies
project [33, 34]. The Notifying Pharmacy project (Farmá-
cias Notificadoras), a partnership between the CVS and
State Boards of Pharmacy, requires a pharmacist be present
during pharmacy operating hours and submit reports of
drug-related problems to the CNMM [35].
Methods
A scoping review of peer reviewed and grey literature
from pharmacy, health, political science, and the social
sciences, pertaining to global actors (e.g. WHO, Global
Fund) and pharmacovigilance, regulatory governance,
accountability and transparency in Brazil was conducted
for this study of governance and pharmacovigilance in
Brazil. The scoping review was used to map the existing
literature and gather a holistic picture of pharmacogo-
vernance in Brazil. Cochrane Collaboration guidelines
for qualitative research were followed for searching,
inclusion, and data extraction [36, 37]. The full search
strategy is presented in Table 1 and follows the STAR-
LITE reporting criteria [36]. The acronym STARLITE
represents sampling strategy, type of study, approaches,
range of years, limits, inclusion and exclusions, terms
used, and electronic sources. Although we narrowly
defined the research question, pre-determined inclusion
and exclusion criteria, and followed a strategy for data
extraction- consistent with a systematic review, we did
not apply quality filters and nor formally assess the
quality of the literature included in our study- consistent
with a scoping review [38].
Search methods
Search methods included entering search terms into rele-
vant databases, organizational websites (e.g., ANVISA)
and hand searching. Sixty-three search terms were entered
into 13 relevant databases on November 17-18, 2013 to
identify literature pertaining to pharmacovigilance, gov-
ernance, transparency, specific global actors, the pharma-
ceutical industry, ANVISA, and civil society (Additional
file 1). Acronyms and full text were entered as search
terms, such as World Health Organization and WHO. All
databases were searched for the same time period which
was the beginning date of the database (e.g., OVID [1946]
and International Pharmaceutical Abstracts [1970]) through
November 18th, 2013. Data were only available through
October 2013 for some of the databases searched. This date
range was selected to capture literature describing global
actors’ influence in Brazil in the years prior to the creation
of ANVISA up to the date of the search. The databases
Fig. 1 Factors influencing pharmacovigilance in Brazil
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searched were Ovid MEDLINE(R) 1946 to November
Week 1 2013, Ovid OLDMEDLINE(R) 1946 to 1965, Ovid
MEDLINE(R) In-Process & Other Non-Indexed Citations
November 15, 2013, Ovid Healthstar 1966 to October
2013, Embase Classic + Embase 1947 to 2013 Week 46,
International Pharmaceutical Abstracts 1970 to October
2013, International Political Science Abstract 1989 to Octo-
ber 2013, Journals@Ovid Full Text November 18, 2013,
Embase 1974 to 2013 November 15, LILACS DATE 1st
mentioned to November 18, 2013, PubMed 1st mention to
November 18, 2013, EBSCO search Oct 16, 2013 and
SciELO 1st mention to Nov 17, 2013. There were no
search restrictions. English, Portuguese, and Spanish
publications were included.
The 1137 records retrieved were derived from: OVID/
Embase (986), LILACS (57), PubMed (89) and EBSCO
(5). After duplicates were removed 358 records remained.
Data from ANVISA, WHO and PAHO websites (4) was
included.
Criteria for selecting studies
Two researchers (KM, PC) read through the titles and
abstracts (all written in English) to determine relevance
to this study. Phase I exclusion criteria comprised publi-
cations that described: 1) vaccines, herbals or animal
studies; 2) pre-market studies (phase I, II, and III); 3)
pharmaceutics methods; 4) randomized controlled trials
or observational studies pertaining to therapeutics or
characterizing drug-specific ADRs and 5) studies that
were retrieved solely because the author was from Brazil,
or a Brazilian reference was cited (Fig. 2). In phase II,
the full text was read to determine inclusion (Table 2).
Full texts written in Portuguese and Spanish were
read; then translated into English using Google translate;
then re-read before determining inclusion. Publications
not meeting inclusion criteria provided background
information to contextualize Brazil’s experience with
pharmacovigilance.
Types of studies included
Fourteen publications met our inclusion criteria
(Table 2). The publications that were included char-
acterized: 1) global interventions in Brazil pertaining
to governance or pharmacovigilance, 2) ANVISA
regulatory governance (e.g., accountability and trans-
parency), and 3) pharmacogovernance in Brazil. All
of the publications that met the inclusion criteria
were read iteratively by the principal author and data
was extracted that was relevant to 1) how global ac-
tors, their policy ideas and instruments influenced
Brazil’s regulatory governance and pharmacovigilance
and 2) how ANVISA’s pharmacogovernance supports
pharmacovigilance.
Data extraction and management
A selective approach to data extraction was employed in
this research [37]. Data specifically related to the study
question(s) and the pharmacogovernance domains were
extracted. A pharmacogovernance framework was used to
analyze the relationship between pharmacogovernance
and pharmacovigilance. The pharmacogovernance do-
mains were established a priori. Our pharmacogovernance
domains were: Policy, Law, and Regulation; Transparency
and Accountability; Participation and Representation;
Equity and Inclusiveness; Effectiveness and Efficiency;
Intelligence and Information; Ethics; Responsiveness;
and Stakeholder coordination (Fig. 3). Quality of the lit-
erature included in this review was neither prioritized nor
formally assessed.
Results
Our scoping review identified fourteen publications on
the topic of governance and ANVISA in Brazil; nine
specifically addressed accountability and/or transpar-
ency. From this sample, four referenced global institu-
tions. Nearly half of the publications (4) were written by
persons internal to ANVISA and described regulation
Table 1 Scoping Review structured According to STARLITE Principles
STARLITE principles
S Selective sampling strategy: Articles selected from pharmacy, health, political science, and the social sciences databases
T All types of studies were included (policy papers, qualitative studies, dissertations)
A Approaches: Subject searching, citation searching, hand-searching, internet searching
R Range (No restrictions): to the beginning of each database—to November 18, 2013
L No Limits
I Inclusion: Global actors and pharmacovigilance, regulatory governance, accountability and transparency in Brazil; Exclusion: Studies describing
1) vaccines, herbals or animal studies; 2) pre-market studies (phase I, II, and III); 3) pharmaceutics methods; 4) randomized controlled trials
or observational studies pertaining to therapeutics or characterizing drug-specific ADRs or 5) did not describe pharmacovigilance in Brazil
T Terms (See Table 1)
E Electronic sources: Ovid MEDLINE(R), Ovid OLDMEDLINE(R), Ovid MEDLINE(R) In-Process & Other Non-Indexed Citations, Ovid Healthstar,
Embase Classic + Embase, International Pharmaceutical Abstracts, International Political Science Abstract, Journals@Ovid Full Text, Embase,
LILACS, PubMed, EBSCO, SciELO, GOOGLE Scholar
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